RxDoctor Payments Data

Genevieve Marie Santayana, DO

Family Medicine · Wynnewood, PANPI 1235588278

Payments from drug & device makers

$792in general payments, 2019–2025

Across 36 payments — averaging $22.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$141
  • AstraZeneca$121
  • AbbVie$110
  • Pfizer$82
  • Lilly USA, LLC$64
  • Abbott$59
  • plus $214 from 9 others

What the payments were for

  • Food & beverage$792100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$792 in reported general payments places this provider in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$89,870
Medicare patients
353
Services billed
931

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban102$67,274
ZenpepLipase/Protease/Amylase17$57,089
RybelsusSemaglutide20$32,069
FarxigaDapagliflozin Propanediol25$26,625
OzempicSemaglutide19$17,702
MyrbetriqMirabegron29$17,134
JanuviaSitagliptin Phosphate19$14,577
EntrestoSacubitril/Valsartan16$13,999
XareltoRivaroxaban18$10,175
Atorvastatin Calcium307$3,966
Lidocaine14$3,377
Rosuvastatin Calcium149$3,358
Midodrine Hcl39$2,588
Levothyroxine Sodium201$2,377
Memantine Hcl44$2,179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$82$67,274102 claims
Novo NordiskRybelsus, Ozempic$141$49,77139 claims
AstraZenecaFarxiga$121$26,62525 claims
NovartisEntresto$17$13,99916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Wynnewood

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →